Sign In
Buy MEDP
$450.82
+5.23 (+1.17%)
At Close: Jun 03, 2026
Medpace (MEDP) Q2 Earnings and Revenues Top Estimates
07:21pm, Monday, 25'th Jul 2022
Medpace (MEDP) delivered earnings and revenue surprises of 8.96% and 1.29%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Baxter (BAX) to Report Q2 Earnings: What's in the Offing?
02:24pm, Monday, 25'th Jul 2022 Zacks Investment Research
Baxter's (BAX) second-quarter results are likely to reflect growth in its Medication Delivery and BioPharma Solutions businesses. Hillrom's products are likely to have boosted sales
The Zacks Analyst Blog Highlights EQT, Medpace Holdings, Crane Holdings, Zions Bancorporation and Hess
10:16am, Monday, 25'th Jul 2022 Zacks Investment Research
EQT, Medpace Holdings, Crane Holdings, Zions Bancorporation and Hess are included in this Analyst Blog.
Should You Buy Medpace (MEDP) Ahead of Earnings?
01:14pm, Friday, 22'nd Jul 2022 Zacks Investment Research
Medpace (MEDP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Can Modest Revenue Growth Aid T-Mobile's (TMUS) Q2 Earnings?
01:12pm, Friday, 22'nd Jul 2022 Zacks Investment Research
T-Mobile (TMUS) is expected to have recorded year-over-year higher revenues in second-quarter 2022, driven by strong sales across its Postpaid, Prepaid and Wholesale businesses.
5 Stocks to Buy Ahead of Q2 Earnings Results Next Week
11:22am, Friday, 22'nd Jul 2022 Zacks Investment Research
Five companies will report second-quarter 2022 earnings results next week. These are: EQT, MEDP, CR, HES and ZION.
5 Stocks to Buy Ahead of Q2 Earnings Results Next Week
08:35am, Friday, 22'nd Jul 2022
Five companies will report second-quarter 2022 earnings results next week. These are: EQT, MEDP, CR, HES and ZION.
$1.4 Million Bet On This Biotechnology Stock? 3 Stocks Insiders Are Buying
10:39am, Thursday, 21'st Jul 2022 Benzinga
Although US stocks closed higher on Wednesday, there were a few notable insider trades.
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the st
Elevance Health (ELV) Q2 Earnings Beat on Higher Premiums
05:32pm, Wednesday, 20'th Jul 2022 Zacks Investment Research
Elevance Health (ELV) hikes adjusted net income estimate for this year to more than $28.70 per share.
Here's How Universal Health (UHS) Looks Ahead of Q2 Earnings
04:29pm, Wednesday, 20'th Jul 2022 Zacks Investment Research
Universal Health's (UHS) second-quarter results are likely to benefit from sound contributions from Acute Care Hospital Services segment. Increased labor costs might partly hurt results.
Icon PLC (ICLR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
02:01pm, Wednesday, 20'th Jul 2022 Zacks Investment Research
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights Medpace, Texas Pacific Land and Delek
09:10am, Wednesday, 20'th Jul 2022 Zacks Investment Research
Medpace, Texas Pacific Land and Delek have been highlighted in this Screen of the Week article.
Factors Likely to Shape Tenet Healthcare's (THC) Q2 Earnings
03:34pm, Monday, 18'th Jul 2022 Zacks Investment Research
Tenet Healthcare's (THC) second-quarter results are likely to reflect the impact of lower contribution of the Hospital segment to overall revenues. The results might partly benefit from a downtrend in
Medpace (MEDP) Reports Next Week: Wall Street Expects Earnings Growth
02:00pm, Monday, 18'th Jul 2022 Zacks Investment Research
Medpace (MEDP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include Medpace, Texas Pacific Land and Delek US Holdings
10:18am, Friday, 15'th Jul 2022 Zacks Investment Research
Medpace, Texas Pacific Land and Delek US Holdings are part of Zacks Screen of the week article.
